WeVote
Log In

Bill

Bill

SB 243

TAX EXEMPTIONS: Provides relative to the sales and use tax exemption for the sale of certain prescription drugs. (gov sig) (EN SEE FISC NOTE LF RV See Note)

2025 Regular Session Introduced by Mike Reese

Louisiana exempts certain prescription drugs from sales and use taxes effective June 2025, reducing medication costs but decreasing state tax revenue.

Signed by the Governor. Becomes Act No. 339.
0
WeVote Research Nonpartisan
Bill Summary · SB 243

Legislative bill overview

SB 243 expands Louisiana's sales and use tax exemption to cover certain prescription drugs that were previously taxable. The bill became effective immediately upon the Governor's signature on June 11, 2025, and is now Act No. 339.

Why is this important

Prescription drug taxation directly affects healthcare affordability for Louisiana residents, particularly low-income individuals managing chronic conditions. Tax exemptions reduce out-of-pocket medication costs, though they also reduce state tax revenue that could fund other services.

Potential points of contention

  • Revenue impact: The fiscal note indicates this creates a tax revenue loss for the state budget, raising questions about which services or programs may be affected
  • Scope definition: The bill's reference to "certain prescription drugs" leaves ambiguity about which medications qualify, potentially creating implementation and fairness concerns
  • Equity considerations: Tax exemptions primarily benefit those who can afford prescriptions; the impact on uninsured or underinsured populations is unclear

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.